Jiangyin International: Raises RemeGen target price to HKD 112, maintains "Buy" rating
I'm PortAI, I can summarize articles.
Jiangyin International raised the target price of RemeGen to HKD 112, maintaining a "Buy" rating. The company's third-quarter revenue increased by 33% year-on-year to CNY 620 million, with sales revenue of TaiTasiPu at CNY 380 million and sales revenue of WeiDiXiTuo at CNY 240 million. Management is confident in achieving the annual product sales revenue growth target of over 30%, and expects to confirm the upfront payment revenue from the BD licensing transactions of TaiTasiPu and RC28 in the fourth quarter
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments